TY - JOUR
T1 - Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes
AU - Bajaj, Mandeep
AU - Pratipanawatr, Thongchai
AU - Berria, Rachele
AU - Pratipanawatr, Wilailak
AU - Kashyap, Sangeeta
AU - Cusi, Kenneth
AU - Mandarine, Lawrence
AU - DeFronzo, Ralph A.
PY - 2002/10/1
Y1 - 2002/10/1
N2 - Splanchnic glucose uptake (SGU) plays a major role in the disposal of an oral glucose load (OGL). To investigate the effect of an elevated plasma free fatty acid (FFA) concentration on SGU in patients with type 2 diabetes, we measured SGU in eight diabetic patients (mean age 51 ± 4 years, BMI 29.3 ± 1.4 kg/m2, fasting plasma glucose 9.3 ± 0.7 mmol/l) during an intravenous Intralipid/heparin infusion and 7-10 days later during a saline infusion. SGU was estimated by the OGL insulin clamp method: subjects received a 7-h euglycemic-hyperinsulinemic clamp (insulin infusion rate = 100 mU·m-2·min-1), and a 75-g OGL was ingested 3 h after starting the insulin clamp. After glucose ingestion, the steady-state glucose infusion rate during the insulin clamp was decreased appropriately to maintain euglycemia. SGU was calculated by subtracting the integrated decrease in glucose infusion rate during the 4-h period after glucose ingestion from the ingested glucose load (75 g). 3-[3H]glucose was infused during the 3-h insulin clamp before glucose ingestion to determine the rates of endogenous glucose production and glucose disappearance (Rd). Intralipid/heparin or saline infusion was initiated 2 h before the start of the OGL clamp. Plasma FFA concentrations were significantly higher during the OGL clamp with the intralipid/heparin infusion than with the saline infusion (2.5 ± 0.3 vs. 0.11 ± 0.02 mmol/l, P < 0.001). During the 3-h insulin clamp period before glucose ingestion, Intralipid/heparin infusion reduced Rd (4.4 ± 0.3 vs. 5.3 ± 0.3 mg·kg-1·min-1, P < 0.01). During the 4-h period after glucose ingestion, SGU was significantly decreased during the intralipid/heparin versus saline infusion (30 ± 2 vs. 37 ± 2%, P < 0.01). In conclusion, an elevation in plasma FFA concentration impairs both peripheral and SGU in patients with type 2 diabetes.
AB - Splanchnic glucose uptake (SGU) plays a major role in the disposal of an oral glucose load (OGL). To investigate the effect of an elevated plasma free fatty acid (FFA) concentration on SGU in patients with type 2 diabetes, we measured SGU in eight diabetic patients (mean age 51 ± 4 years, BMI 29.3 ± 1.4 kg/m2, fasting plasma glucose 9.3 ± 0.7 mmol/l) during an intravenous Intralipid/heparin infusion and 7-10 days later during a saline infusion. SGU was estimated by the OGL insulin clamp method: subjects received a 7-h euglycemic-hyperinsulinemic clamp (insulin infusion rate = 100 mU·m-2·min-1), and a 75-g OGL was ingested 3 h after starting the insulin clamp. After glucose ingestion, the steady-state glucose infusion rate during the insulin clamp was decreased appropriately to maintain euglycemia. SGU was calculated by subtracting the integrated decrease in glucose infusion rate during the 4-h period after glucose ingestion from the ingested glucose load (75 g). 3-[3H]glucose was infused during the 3-h insulin clamp before glucose ingestion to determine the rates of endogenous glucose production and glucose disappearance (Rd). Intralipid/heparin or saline infusion was initiated 2 h before the start of the OGL clamp. Plasma FFA concentrations were significantly higher during the OGL clamp with the intralipid/heparin infusion than with the saline infusion (2.5 ± 0.3 vs. 0.11 ± 0.02 mmol/l, P < 0.001). During the 3-h insulin clamp period before glucose ingestion, Intralipid/heparin infusion reduced Rd (4.4 ± 0.3 vs. 5.3 ± 0.3 mg·kg-1·min-1, P < 0.01). During the 4-h period after glucose ingestion, SGU was significantly decreased during the intralipid/heparin versus saline infusion (30 ± 2 vs. 37 ± 2%, P < 0.01). In conclusion, an elevation in plasma FFA concentration impairs both peripheral and SGU in patients with type 2 diabetes.
UR - http://www.scopus.com/inward/record.url?scp=0036789244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036789244&partnerID=8YFLogxK
U2 - 10.2337/diabetes.51.10.3043
DO - 10.2337/diabetes.51.10.3043
M3 - Article
C2 - 12351445
SN - 0012-1797
VL - 51
SP - 3043
EP - 3048
JO - Diabetes
JF - Diabetes
IS - 10
ER -